PACS vs CCRN

For growth investors, PACS Group, Inc.

(PACS) is the stronger pick with 29. 3% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). PACS Group, Inc. (PACS) offers the better valuation at 27. 6x trailing P/E (16. 2x forward), making it the more compelling value choice. Analysts rate PACS Group, Inc. (PACS) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, PACS Group, Inc.

is actually cheaper at 16. 2x.

Over the past 5 years, PACS Group, Inc.

(PACS) delivered a total return of +46. 2%, compared to -22. 5% for Cross Country Healthcare, Inc. (CCRN). Over 10 years, the gap is even starker: PACS returned +46. 2% versus CCRN's -10. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), PACS Group, Inc.

(PACS) is the lower-risk stock at 0. 64β versus Cross Country Healthcare, Inc. 's 0. 78β — meaning CCRN is approximately 22% more volatile than PACS relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 3% for PACS Group, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), PACS Group, Inc.

(PACS) is pulling ahead at 29. 3% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: PACS Group, Inc. grew EPS 221. 1% year-over-year, compared to -565. 9% for Cross Country Healthcare, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

PACS Group, Inc.

(PACS) is the more profitable company, earning 3. 6% net margin versus -9. 0% for Cross Country Healthcare, Inc. — meaning it keeps 3. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PACS leads at 5. 9% versus -0. 3% for CCRN. At the gross margin level — before operating expenses — PACS leads at 21. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, PACS Group, Inc.

(PACS) trades at 16. 2x forward P/E versus 133. 8x for Cross Country Healthcare, Inc. — 117. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PACS: 32. 9% to $44. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, PACS Group, Inc.

(PACS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 64)). Both have compounded well over 10 years (PACS: +46. 2%, CCRN: -10. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (PACS (Financial Services) and CCRN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: PACS is a small-cap high-growth stock; CCRN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.